PODCAST
Patch Shortage, Heart Risk, and the Cancer Question That Won't Go Away
March 23, 2026·9:34·Episode 1
Quick Summary
The FDA's removal of black box warnings has triggered an estrogen patch shortage, new research links early menopause to significantly higher heart disease risk, and a promising study suggests vaginal estrogen may be safe for breast cancer survivors.
Listen On
Patch Shortage, Heart Risk, and the Cancer Question That Won't Go Away
0:000:00
Key Takeaways
- ✦FDA removed black box warnings from HRT — demand surged and estrogen patches are now in short supply
- ✦Women entering menopause before age 45 face 40% higher cardiovascular disease risk
- ✦New PubMed research suggests vaginal estrogen does not increase cancer recurrence in breast cancer survivors
Sources & References
- 📰CBS News — Estrogen patch shortage follows FDA policy changes
- 📰Healthline — Early menopause linked to 40% higher cardiovascular disease risk
- 🔬PubMed Study — Vaginal estrogen safety research for breast cancer survivors
- Questions about hormone therapy options? Always consult with your healthcare provider about what's right for your specific situation.
Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.